Investing
Cathie Wood's ARK Invest Sells Over 350,000 Shares of Takeda Pharma
Published:
Last Updated:
One ARK Invest exchange-traded fund run by ETF star Cathie Wood sold over 350,000 shares of Takeda Pharmaceutical Co. Ltd. (NYSE: TAK) on Wednesday, as the share price of this fund traded relatively flat in the day’s session. Its share price has greatly improved over the past year.
ARK Genomic Revolution ETF (NYSEARCA: ARKG) sold 366,228 shares of Takeda. At Wednesday’s closing price, this would have valued this sale at roughly $6.2 million. This is only a small fraction of the total holdings. This fund is up 84% over the past 52 weeks.
Here is a quick look at all the other sales that took place across all ARK ETFs:
Fund | Ticker | Company | Shares |
---|---|---|---|
ARKF | TCSLI | TCS GROUP HOLDING PLC | 35,354 |
ARKG | NVS | NOVARTIS AG | 128,903 |
ARKG | PSTI | PLURISTEM THERAPEUTICS INC | 1,357 |
ARKG | SRPT | SAREPTA THERAPEUTICS INC | 22,178 |
ARKG | TAK | TAKEDA PHARMACEUTICAL CO LTD | 366,228 |
ARKQ | GLEO | GALILEO ACQUISITION CORP | 325,800 |
ARKQ | NVDA | NVIDIA CORP | 4,050 |
ARKQ | RAVN | RAVEN INDUSTRIES INC | 12,814 |
ARKQ | TCEHY | TENCENT HOLDINGS LTD | 36,315 |
ARKW | TCEHY | TENCENT HOLDINGS LTD | 46,793 |
ARKW | PSTG | PURE STORAGE INC | 187,131 |
ARKW | NET | CLOUDFLARE INC | 69,294 |
Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St.
Credit card companies are pulling out all the stops, with the issuers are offering insane travel rewards and perks.
We’re talking huge sign-up bonuses, points on every purchase, and benefits like lounge access, travel credits, and free hotel nights. For travelers, these rewards can add up to thousands of dollars in flights, upgrades, and luxury experiences every year.
It’s like getting paid to travel — and it’s available to qualified borrowers who know where to look.
We’ve rounded up some of the best travel credit cards on the market. Click here to see the list. Don’t miss these offers — they won’t be this good forever.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.